Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma

Nature Reviews Cancer

Volumn 13, Issue 2, 2013, Pages 123-135

  Arzumanyan, Alla ^a   Reis, Helena M G P V ^b   Feitelson, Mark A ^a  

^a Temple University   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BMS 86094; BMS 986094; HEPATITIS B VACCINE; HEPATITIS C VACCINE; INTERFERON; MIRAVIRSEN; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; SORAFENIB; TUMOR MARKER; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; CANCER PREVENTION; CANCER THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC LIVER DISEASE; DISEASE ASSOCIATION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; FIBROGENESIS; GENE EXPRESSION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPOXIA; INNATE IMMUNITY; LIVER CELL CARCINOMA; NONHUMAN; ONCOGENE; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SENESCENCE; TUMOR SUPPRESSOR GENE; VIRUS GENOME; VIRUS REPLICATION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; HEPACIVIRUS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS;

EID: 84873020277     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3449     Document Type: Review

References (182)

1. El-Serag, H. B. & Rudolph, K. L. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 132, 2557-2576 (2007
2. Beasley, R. P., Hwang, L. Y., Lin, C. C. & Chien, C. S. Hepatocellular carcinoma & HBV. A prospective study of 22,707 men in Taiwan. Lancet 2, 1129-1133 (1981
3. Lee, W. M. Hepatitis B virus infection. N. Engl. J. Med. 337, 1733-1745 (1977
4. Roberts, L. R. & Gores, G. J. Hepatocellular carcinoma: Molecular pathways and new therapeutic targets. Semin. Liver Dis. 25, 212-225 (2005
5. Sherman, M. Risk of hepatocellular carcinoma in hepatitis B and prevention through treatment. Cleve. Clin. J. Med. 76, S6-S9 (2009
6. Nguyen, V. T., Law, M. G. & Dore, G. J. Hepatitis B-related hepatocellular carcinoma: Epidemiological characteristics and disease burden. J. Viral Hepat. 16, 453-463 (2009
7. Strader, D B. et al.Diagnosis, management, and treatment of hepatitis C. Hepatology 39, 1147-1171 (2004
8. Venook, A. P., Papandreou, C., Furuse, J. & de Guevara, L. L. The incidence and epidemiology of hepatocellular carcinoma: A global and regional perspective. Oncologist 15, S5-S13 (2010
9. Poon, R. T. et al.Improving survival results after resection of hepatocellular carcinoma: A prospective study of 377 patients over 10 years. Ann. Surg. 234, 63-70 (2001
10. Llovet, J. M. et al.Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008
11. Maddrey, W. C. Hepatitis B, an important public health issue. J. Med. Virol. 61, 362-366 (2000
12. Smyth, R., Keenan, E., Dorman, A. & O'Connor, J. Hepatitis C infection among injecting drug users attending the National Drug Treatment Center. Ir. J. Med. Sci. 164, 267-268 (1995
13. Ni, Y. H. & Chen, D. S. Hepatitis B vaccination in children: The Taiwan experience. Pathol. Biol. (Paris) 58, 296-300 (2010
14. Pawlotsky, J. M. Hepatitis C virus population dynamics during infection. Curr. Top. Microbiol. Immunol. 299, 261-284 (2006
15. Papatheodoridis, G. V., Lampertico, P., Manolakopoulos, S. & Lok, A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review. J. Hepatol. 53, 348-356 (2010
16. Cohen, J. Infectious disease. Despite setbacks, optimism on drugs for hepatitis C. Science. 337, 1450-1451 (2012
17. Rehermann, B. & Nascimbeni, M. Immunology of hepatitis B virus and hepatitis C virus infection. Nature Rev. Immunol. 5, 215-229 (2005
18. Sun, B. S. et al.Hepatitis C virus replication in stably transfected HepG2 cells promotes hepatocellular growth and tumorigenesis. J. Cell. Physiol. 201, 447-458 (2004
19. Sells, M. A., Chen, M. L. & Acs, G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc. Natl Acad. Sci. USA 84, 1005-1009 (1987
20. Fattovich, G., Stroffolini, T., Zagni, I. & Donato, F. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology 127, S35-S50 (2004
21. Guidotti, L. G. et al.Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4, 25-36 (1996
22. Akbar, S. M. F., Inaba. K. & Onji, M. Upregulation of MHC class II antigen on dendritic cells from hepatitis B virus transgenic mice by interferon-γ abrogation of immune response defect to a T-cell-dependent antigen. Immunology 87, 519-527 (1996
23. Yang, Y. F. et al.Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: A meta-analysis. J. Viral Hepat. 16, 265-271 (2009
24. Chow, W C. et al.Re-treatment with interferon alfa of patients with chronic hepatitis C. Hepatology 27, 1144-1148 (1998
25. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. Cell 144, 646-674 (2011
26. Levrero, M. et al.Control of cccDNA function in hepatitis B virus infection. J. Hepatol. 51, 581-592 (2009
27. Jin, Y. M., Yun, C., Park, C., Wang, H. J. & Cho, H. Expression of hepatitis B virus X protein is closely correlated with the high periportal inflammatory activity of liver diseases. J. Viral Hepat. 8, 322-330 (2001
28. Carreno, V., Bartolome, J., Castillo, I. & Quiroga, J. A. Occult hepatitis B virus and hepatitis C virus infections. Rev. Med. Virol. 18, 139-157 (2008
29. Chen, S. Y. et al.Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein. J. Biol. Chem. 278, 591-607 (2003
30. Lin, L., Verslype, C., van Pelt, J. F., van Ranst, M. & Fevery, J. Viral interaction and clinical implications of coinfection of hepatitis C virus with other hepatitis viruses. Eur. J. Gastroenterol. Hepatol. 18, 1311-1319 (2006
31. Tamori, A. et al.Frequent detection of hepatitis B virus DNA in hepatocellular carcinoma of patients with sustained virologic response for hepatitis C virus. J. Med. Virol. 81, 1009-1014 (2009
32. Liu, Z. & Hou, J. Hepatitis B virus (HBV) and hepatitis C virus (HCV) dual infection. Int. J. Med. Sci. 3, 57-62 (2006
33. Isogawa, M., Robek, M. D., Furuichi, Y. & Chisari, F. V. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J. Virol. 79, 7269-7272 (2005
34. Wu, J. et al.Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 49, 1132-1140 (2009
35. Beg, A. A. & Baltimore, D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science 274, 782-784 (1996
36. Su, F. & Schneider, R. J. Hepatitis B virus HBx protein activates transcription factor NF-κB by acting on multiple cytoplasmic inhibitors of rel-related proteins. J. Virol. 70, 4558-4566 (1996
37. Zhang, Z. et al.Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients. Hepatology 53, 73-85 (2011
38. van der Molen, R G. et al.Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology 40, 738-746 (2004
39. Yoo, Y. D. et al.Regulation of transforming growth factor-β 1 expression by the hepatitis B virus (HBV) X transactivator. Role in HBV pathogenesis. J. Clin. Invest. 97, 388-395 (1996
40. Lopes, A. R. et al.Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. J. Clin. Invest. 118, 1835-1845 (2008
41. Saito, T., Owen, D. M., Jiang, F., Marcotrigiano, J. & Gale, M. Jr. Innate immunity induced by composition-dependent RIG-1 recognition of hepatitis C virus RNA. Nature 454, 523-527 (2008
42. Guo, J. T., Sohn, J. A., Zhu, Q. & Seeger, C. Mechanism of the interferon α response against hepatitis C virus replicons. Virology 325, 71-81 (2004
43. Li, K. et al.Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc. Natl Acad. Sci. USA 102, 2992-2997 (2005
44. Heim, M. H., Moradpour, D. & Blum, H. E. Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. J. Virol. 73, 8469-8475 (1999
45. Polyak, S. J. et al.Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J. Virol. 75, 6095-6106 (2001
46. Taylor, D. R., Shi, S. T., Romano, P. R., Barber, G. N. & Lai, M. M. Inhibition of the interferon inducible protein kinase PKR by HCV E2 protein. Science 285, 107-110 (1999
47. Freeman, A. J. et al.The presence of an intrahepatic cytotoxic T lymphocyte response is associated with low viral load in patients with chronic hepatitis C virus infection. J. Hepatol. 38, 349-356 (2003
48. Thimme, R. et al.Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med. 194, 1395-1306 (2001
49. Jahan, S., Ashfaq, U. A., Khaliq, S., Samreen, B. & Afzal, N. Dual behavior of HCV core gene in regulation of apoptosis is important in progression of HCC. Infect. Genet. Evol. 12, 236-239 (2012
50. Ng, S. A. & Lee, C. Hepatitis B virus X gene and hepatocarcinogenesis. J. Gastroenterol. 46, 974-990 (2011
51. Pan, J., Lian, Z., Wallett, S. & Feitelson, M. A. The hepatitis B x antigen effector, URG7, blocks tumour necrosis factor α-mediated apoptosis by activation of phosphoinositol 3-kinase and β-catenin. J. Gen. Virol. 88, 3275-3285, 2007
52. Nakamura, H., Aoki, H., Hino, O. & Moriyama, M. HCV core protein promotes heparin binding EGF-like growth factor expression and activates Akt. Hepatol. Res. 41, 455-462 (2011
53. Jiang, Y. F. et al.The oncogenic role of NS5A of hepatitis C virus is mediated by up-regulation of survivin gene expression in the hepatocellular cell through p53 and NF-κB pathways. Cell Biol. Int. 35, 1225-1232 (2011
54. Jin, Y. et al.The immune reactivity role of HCV induced liver infiltrating lymphocytes in hepatocellular damage. J. Clin. Immunol. 17, 140-153 (1997
55. Vandermeeren, A. M. et al.Subcellular forms and biochemical events triggered in human cells by HCV polyprotein expression from a viral vector. Virol. J. 5, 102-121 (2008
56. Clippinger, A. J. & Bouchard, M. J. Hepatitis B virus HBx protein localizes to mitochondria in primary rat hepatocytes and modulates mitochondrial membrane potential. J. Virol. 82, 6798-6811 (2008
57. Bhargava, A. et al.Occult hepatitis C virus elicits mitochondrial oxidative stress in lymphocytes and triggers PI3-kinase-mediated DNA damage response. Free Radic. Biol. Med. 51, 1806-1814 (2011
58. Cho, H. K., Cheong, K. J., Kim, H. Y. & Cheong, J. Endoplasmic reticulum stress induced by hepatitis B virus X protein enhances cyclo-oxygenase 2 expression via activating transcription factor 4. Biochem. J. 435, 431-439 (2011
59. Yang, F. et al.Expression of hepatitis B virus proteins in transgenic mice alters lipid metabolism and induces oxidative stress in the liver. J. Hepatol. 48, 12-19 (2008
60. Srisuttee, R. et al.Up-regulation of Foxo4 mediated by hepatitis B virus X protein confers resistance to oxidative stress-induced cell death. Int. J. Mol. Med. 28, 255-260 (2011
61. Yang, B. & Bouchard, M. J. The hepatitis B virus X protein elevates cytosolic calcium signals by modulating mitochondrial calcium uptake. J. Virol. 86, 313-327 (2012
62. Bouchard, M. J., Puro, R. J., Wang, L. & Schneider, R. J. Activation and inhibition of cellular calcium and tyrosine kinase signaling pathways identify targets of the HBx protein involved in hepatitis B virus replication. J. Virol. 77, 7713-7719 (2003
63. Fujinaga, H., Tsutsumi, T., Yotsuyanagi, H., Moriya, K. & Koike, K. Hepatocarcinogenesis in hepatitis C: HCV shrewdly exacerbates oxidative stress by modulating both production and scavenging of reactive oxygen species. Oncology 81, S11-S17 (2011
64. Ripoli, M. et al.Hepatitis C virus-linked mitochondrial dysfunction promotes hypoxia-inducible factor 1α-mediated glycolytic adaptation. J. Virol. 84, 647-660 (2010
65. Quarato, G. et al.Targeting mitochondria in the infection strategy of the hepatitis C virus. Int. J. Biochem. Cell Biol. 45, 156-166 (2012
66. Merquiol, E. et al.HCV causes chronic endoplasmic reticulum stress leading to adaptation and interference with the unfolded protein response. PLoS ONE 6, e24660 (2011
67. Li, J. et al.Subversion of cellular autophagy machinery by hepatitis B virus for viral envelopment. J. Virol. 85, 6319-6333 (2011
68. Key, P. Y. & Chen, S. S. Activation of the unfolded protein response and autophagy after hepatitis C virus infection suppresses innate antiviral immunity in vitro. J. Clin. Invest. 121, 37-56 (2011
69. Dreux, M., Gastaminza, P., Wieland, S. F. & Chisari, F. V. The autophagy machinery is required to initiate hepatitis C virus replication. Proc. Natl Acad. Sci. USA 33, 14046-14051 (2009
70. Ogata, M. et al.Autophagy is activated for cell survival after endoplasmic reticular stress. Mol. Cell. Biol. 24, 9220-9231 (2006
71. Liu, T. T. et al.A case-control study of the relationship between hepatitis B virus DNA level and risk of hepatocellular carcinoma in Qidong, China. World J. Gastroenterol. 14, 3059-3063 (2008
72. Vrancken, K., Poeshuyse, J. & Liekens, S. Angiogenic activity of hepatitis B and C viruses. Antivir. Chem. Chemother. 22, 159-170 (2012
73. Moon, E. J. et al.Hepatitis B virus X protein induces angiogenesis by stabilizing hypoxia-inducible factor-1α. FASEB J. 18, 382-384 (2004
74. Yoo, Y. G. et al.Hepatitis B virus X protein enhances transcriptional activity of hypoxia-inducible factor-1α through activation of mitogen activated protein kinase pathway. J. Biol. Chem. 278, 39076-39084 (2003
75. Keith, B. & Simon M. C. Hypoxia-inducible facgtors, stem cells, and cancer. Cell 129, 465-472 (2007
76. Sanz-Camern, P. et al.Hepatitis B virus promotes angiopoietin-2 expression in liver tissue. Role of HBV X protein. Am. J. Pathol. 169, 1215-1222 (2006
77. Abe, M. et al.Hepatitis C virus core protein up-regulates the expression of vascular endothelial growth factor via the nuclear factor-κB/hypoxia- inducible factor-1α axis under hypoxic conditions. Hepatol. Res. 42, 591-600 (2012
78. Schiffer, E. et al.Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 41, 307-314 (2005
79. Liu, J. et al.Increased expression of c-erbB-2 in liver is associated with HBxAg expression and shorter survival in patients with hepatocellular carcinoma. Int. J. Cancer 125, 1894-1901 (2009
80. El Bassuoni, M. A., Talaat, R. M., Ibrahim, A. A. & Shaker, O. T. TGF-β1 and C-erb-B2 neu oncoprotein in Egyptian HCV related chronic liver disease and hepatocellular carcinoma patients. Egypt J. Immunol. 15, 39-50 (2008
81. Collado, M. et al.Tumour biology: Senescence in premalignant tumours. Nature 436, 642 (2005
82. Benn, J. & Schneider, R. J. Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade. Proc. Natl Acad. Sci. USA 91, 10350-10354 (1994
83. Oishi, N. et al.Hepatitis B virus X protein overcomes oncogenic ras-induced senescence in human immortalized cells. Cancer Sci. 98, 1540-1548 (2007
84. Tanaka, S. & Shigeki, A. Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies. J. Gastroenterol. 46, 289-296 (2011
85. Chung, T. W., Lee, Y. C. & Kim, C. H. Hepatitis B viral HBx induces MMP-9 gene expression through activation of ERK and PI-3K/AKT pathways: Involvement of invasive potential. FASEB J. 18, 1123-1125 (2004
86. Tarn, C., Lee, S., Hu, Y., Ashendel, C. & Andrisani, O. M. Hepatitis B virus X protein differentially activates RAS-RAF-MAPK & JNK pathways in X-transforming versus non-transforming AML12 hepatocytes. J. Biol. Chem. 276, 34671-34680 (2001
87. Hoare, M., Das, T. & Alexander, G. Ageing, telomeres, senescence, and liver injury. J. Hepatol. 53, 950-961 (2010
88. Kang, T. W. et al.Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 479, 547-551 (2011
89. Huang, J., Wang, Y., Guo, Y. & Sun, S. Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology 52, 60-70 (2010
90. Benegiamo, G. et al.DNA methyltransferases 1 and 3b expression in Huh-7 cells expressing HCV core protein of different genotypes. Dig. Dis. Sci. 57, 1598-1603 (2012
91. Toyota, M. & Suzuki, H. Epigenetic drivers of genetic alterations. Adv. Genet. 70, 309-323 (2010
92. Kao, C. F., Chen, S. Y., Chen, J. Y. & Wu Lee, Y. H. Modulation of p53 transcription regulatory activity and post-translational modification by hepatitis C virus core protein. Oncogene 23, 2472-2483 (2004
93. Wang, X. W. et al.Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl Acad. Sci. USA 91, 2230-2234 (1994
94. Zhao, J. et al.Epigenetic silence of ankyrin-repeat-containing, SH3-domain-containing, and proline-rich-region-containing protein 1 (ASPP1) and ASPP2 genes promotes tumor growth in hepatitis B virus-positive hepatocellular carcinoma. Hepatology 51, 142-153 (2010
95. Machida, K. et al.Hepatitis C virus inhibits DNA damage-repair through reactive oxygen and nitrogen species and by Interfering with the ATM-NBS1/Mre11/ Rad50 DNA repair pathway in monocytes and hepatocytes. J. Immunol. 185, 6985-6998 (2010
96. Park, S. H., Jung, J. K., Lim, J. S., Tiwari, I. & Jang, K. L. Hepatitis B virus X protein overcomes all-trans retinoic acid-induced cellular senescence by down-regulating levels of p16 and p21 via DNA methylation. J. Gen. Virol. 92, 1309-1317 (2011
97. Lim, J. S., Park, S. H. & Jang, K. L. Hepatitis C virus core protein overcomes stress-induced premature senescence by down-regulating p16 expression via DNA methylation. Cancer Lett. 321, 154-161 (2012
98. Zender, L. et al.An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 135, 852-864 (2008
99. Meek, D. W. Tumour suppression by p53: A role for the DNA damage response? Nature Rev. Cancer 9, 714-723 (2009
100. Gramantieri, L. et al.Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res. 67, 6092-6099 (2007
101. Hao, M., Zheng, S., Ding, H. & Huang, A. Regulation of microRNA-122 on HBV replication by targeting HBx sequence. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 28, 784-789, 803 (2011) (in Chinese
102. Jangra, R. K., Yi, M. & Lemon, S. M. Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122. J. Virol. 84, 6615-6625 (2010
103. Ura, S. et al.Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 49, 1098-10112 (2009
104. Guarino. M., Tosoni, A., Nebuloni, M. Direct contribution of epithelium to organ fibrosis: Epithelial-mesenchymal transition. Hum. Pathol. 40, 1365-1376 (2009
105. Bedossa, P. & Paradis, V. Liver extracellular matrix in health and disease. J. Pathol. 200, 504-515 (2003
106. Gressner, O. A. Weiskirchen, R. & Gressner, A. M. Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options. Comp. Hepatol. 6, 7 (2007
107. Zeisberg, M. et al.Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J. Biol. Chem. 282, 23337-23347 (2007
108. Kalluri, R. EMT: When epithelial cells decide to become mesenchymal-like cells. J. Clin. Invest. 119, 1417-1419 (2009
109. Castilla, A., Prieto, J. & Fausto, N. Transforming growth factors β 1 and α in chronic liver disease. Effects of interferon alfa therapy. N. Engl. J. Med. 324, 933-940 (1991
110. Barrallo-Gimeno, A. & Nieto, M. A. The Snail genes as inducers of cell movement survival: Implications in development and cancer. Development 132, 3151-3161 (2005
111. van Ziji, F. et al.Epithelial-mesenchymal transition in hepatocellular carcinoma. Future Oncol. 6, 1169-1179 (2009
112. Lee, D. K. et al.The hepatitis B virus encoded oncoprotein pX amplifies TGF-β family signaling through direct interaction with Smad4: Potential mechanism of hepatitis B virus-induced liver fibrosis. Genes Dev. 15, 455-466 (2001
113. Xu, J. et al.TGF-β-induced epithelial-to-mesenchymal transition. Cell Res. 19, 156-172 (2009
114. Battaglia, S. et al.Liver cancer-derived hepatitis C virus core proteins shift TGF-β responses from tumor suppression to epithelial-mesenchymal transition. PLoS ONE 4, e4355 (2009
115. Zhu, Q. et al.miR-21 promotes migration and invasion by the miR-21-PDCD4-AP-1 feedback loop in human hepatocellular carcinoma. Oncol. Rep. 27, 1660-1668 (2012
116. Wu, C. Y., Tsai, Y. P., Wu, M. Z., Teng, S. C. & Wu, K. J. Epigenetic reprogramming and post-transcriptional regulation during the epithelial-mesenchymal transition. Trends Genet. 28, 454-463 (2012
117. Shih, W. L., Kuo, M. L., Chuang, S. E., Cheng, A. L. & Doong, S. L. Hepatitis B virus X protein activates a survival signaling by linking SRC to phosphatidylinositol 3-kinase. J. Biol. Chem. 278, 31807-31813 (2003
118. Pfannkuche, A. et al.c-Src is required for complex formation between the hepatitis C virus-encoded proteins NS5A and NS5B: A prerequisite for replication. Hepatology 53, 1127-1136 (2011
119. Yang, S. Z. et al.HBx protein induces EMT through c-Src activation in SMMC-7721 hepatoma cell line. Biochem. Biophys. Res. Commun. 382, 555-560 (2009
120. Lara-Pezzi, E., Roche, S., Andrisani, O. M., Sαnchez- Madrid, F. & Lσpez-Cabrera, M. The hepatitis B virus HBx protein induces adherens junction disruption in a src-dependent manner. Oncogene 20, 3323-3331 (2001
121. Arzumanyan, A. et al.Epigenetic repression of E-cadherin expression by hepatitis B virus x antigen in liver cancer. Oncogene 31, 563-572 (2012
122. Akkari, L. et al.Hepatitis C viral protein NS5A induces EMT and participates in oncogenic transformation of primary hepatocyte precursors. J. Hepatol. 57, 1021-1028 (2012
123. Ripoli, M. et al.Hypermethylated levels of E-cadherin promoter in Huh-7 cells expressing the HCV core protein. Virus Res. 160, 74-81 (2011
124. Shin, J. Y. et al.HCV core protein promotes liver fibrogenesis via up-regulation of CTGF with TGF-β1. Exp. Mol. Med. 37, 138-145 (2005
125. Ming-Ju, H., Yih-Shou, H., Tzy-Yen, C. & Hui- Ling, C. Hepatitis C virus E2 protein induce reactive oxygen species (ROS)-related fibrogenesis in the HSC-T6 hepatic stellate cell line. J. Cell. Biochem. 112, 233-243 (2011
126. Oishi, N. & Wang, X. W. Novel therapeutic strategies for targeting liver cancer stem cells. Int. J. Biol. Sci. 7, 517-535 (2011
127. Tong, C. M., Ma, S. & Guan, X. Y. Biology of hepatic cancer stem cells. J. Gastroenterol. Hepatol. 26, 1229-1237 (2011
128. Tomuleasa, C. et al.Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma. J. Gastrointestin. Liver Dis. 19, 61-67 (2010
129. Arzumanyan, A et al.Does the hepatitis B antigen HBx promote the appearance of liver cancer stem cells? Cancer Res. 71, 3701-3708 (2011
130. Zhao, R. C., Zhu, Y. S. & Shi, Y. New hope for cancer treatment: Exploring the distinction between normal adult stem cells and cancer stem cells. Pharmacol. Ther. 119, 74-82 (2008
131. Monk, M. & Holding, C. Human embryonic genes re-expressed in cancer cells. Oncogene 20, 8085-8091 (2001
132. Yamashita, T., Budhu, A., Forgues, M. & Wang, X. W. Activation of hepatic stem cell marker EpCAM by Wnt-β-catenin signaling in hepatocellular carcinoma. Cancer Res. 67, 10831-10839 (2007
133. Schoenhals, M. et al.Embryonic stem cell markers expression in cancers. Biochem. Biophys. Res. Commun. 383, 157-162 (2009
134. Ali, N. et al.Hepatitis C virus-induced cancer stem cell-like signatures in cell culture and murine tumor xenografts. J. Virol. 85, 12292-12303 (2011
135. Katoh, M. & Katoh, M. WNT signaling pathway and stem cell signaling network. Clin. Cancer Res. 13, 4042-4045 (2007
136. Lu, T. Y. et al.Epithelial cell adhesion molecule regulation is associated with the maintenance of the undifferentiated phenotype of human embryonic stem cells. J. Biol. Chem. 285, 8719-8732 (2010
137. Yamashita, T. et al.EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/ progenitor cell features. Gastroenterology 136, 1012-1024 (2009
138. Ji, J. et al.Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 50, 472-480 (2009
139. Li, Z. & Rich, J. N. Hypoxia and hypoxia inducible factors in cancer stem cell maintenance. Curr. Top. Microbiol. Immunol. 345, 21-30 (2010
140. Kaidi, A., Williams, A. C. & Paraskeva, G. Interaction between β-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nature Cell Biol. 9, 210-217 (2007
141. Hoffmeyer, K. et al.Wnt/β-catenin signaling regulates telomerase in stem cells and cancer cells. Science 336, 1549-1554 (2012
142. Yang, J. & Weinberg, R. A. Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Dev. Cell. 14, 818-829 (2008
143. Copple, B. L. Hypoxia stimulates hepatocyte epithelial to mesenchymal transition by hypoxia-inducible factor and transforming growth factor-β-dependent mechanisms. Liver Int. 30, 669-682 (2010
144. Mani, S. A. et al.The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715 (2008
145. Kurrey, N. K. et al.Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 27, 2059-2068 (2009
146. Yamashita, T. et al.EpCAM and a-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 68, 1451-1461 (2008
147. Niu, D., Feng, H. & Chen, W. N. Proteomic analysis of HBV-associated HCC: Insights on mechanisms of disease onset and biomarker discovery. J. Proteom. 73, 1283-1290 (2010
148. Feitelson, M. A. & Lee, J. Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. Cancer Lett. 252, 157-170 (2007
149. Hsu, S. et al.Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J. Clin. Invest. 122, 2871-2883 (2012
150. Tsai, W. C. et al.MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J. Clin. Invest. 122, 2884-2897 (2012
151. Bolondi, L. et al.Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: A cost effective analysis. Gut 48, 251-259 (2001
152. Sterling, R. K. et al.Utility of Lens culinaris agglutinin-reactive fraction of α-fetoprotein and des-γ-carboxy prothrombin, alone or in combination, as. biomarkers for hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 7, 104-113 (2009
153. Bertino, G. et al.Hepatocellualar carcinoma serum markers. Semin. Oncol. 39, 410-433 (2012
154. Uemura, M. et al.Identification of the antigens predominantly reacted with serum from patients with hepatocellular carcinoma. Cancer 97, 2474-2479 (2003
155. Anders, R. A. et al.cDNA microarray analysis of macroregenerative and dysplastic nodules in end-stage hepatitis C virus-induced cirrhosis. Am. J. Pathol. 162, 991-1000 (2003
156. Paradis, V. et al.Molecular profiling of hepatocellular carcinomas (HCC) using a large-scale real-time RT-PCR approach. Determination of a molecular diagnostic index. Am. J. Pathol. 163, 733-741 (2003
157. Lee, C. F., Ling, Z. Q., Zhao, T. & Lee, K. R. Distinct expression patterns in hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma. World J. Gastroenterol. 14, 6072-6077 (2008
158. Maass, T. et al.Microarray-based gene expression analysis of hepatocellular carcinoma. Curr. Genomics 11, 261-268 (2010
159. Sun, M. et al.Expression profile reveals novel prognostic biomarkers in hepatocellular carcinoma. Front. Biosci. (Elite Ed) 2, 829-840 (2010
160. Marquardt, J. U., Galle, P. R. & Teufel, A. Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): An emerging field for advanced technologies. J. Hepatol. 56, 267-275 (2012
161. Abu Dayyeh, B. K. et al.A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology 141, 141-149 (2011
162. Tanabe, K. E. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA 299, 53-60 (2008
163. Thomas, D. L. et al.Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461, 798-801 (2009
164. Ge, D. et al.Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399-401 (2009
165. Qi, P. et al.No association of EGF 5'UTR variant A61G and hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. Pathology 41, 555-560 (2009
166. Li, W. et al.Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population. Liver Int. 31, 1118-1126 (2011
167. Martin, M. P. et al.IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J. Infect. Dis. 202, 1749-1753 (2010
168. Qi, P. et al.-509C>T polymorphism in the TGF-β1 gene promoter, impact on the hepatocellular carcinoma risk in Chinese patients with chronic hepatitis B virus infection. Cancer Immunol. Immunother. 58, 1433-1440 (2009
169. Okamoto, K. et al.The genotypes of IL-1 β and MMP-3 are associated with the prognosis of HCV-related hepatocellular carcinoma. Intern. Med. 49, 887-895 (2010
170. Llovet, J. M. & Bruix, J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48, 1312-1327 (2008
171. Menzo, S. et al.Trans-activation of epidermal growth factor receptor gene by the hepatitis B virus X-gene product. Virology 196, 878-882 (1993
172. Diao, J. et al.Hepatitis C virus induces epidermal growth factor receptor activation via CD81 binding for viral internalization and entry. J. Virol. 86, 10935-10949 (2012
173. Sedlaczek, N., Hasilik, A., Neuhaus, P., Schuppan, D. & Herbst, H. Focal overexpression of insulin-like growth factor 2 by hepatocytes and cholangiocytes in viral liver cirrhosis. Br. J. Cancer 88, 733-739 (2003
174. Liu, J. et al.Enhancement of canonical Wnt/β-catenin signaling activity by HCV core protein promotes cell growth of hepatocellular carcinoma cells. PLoS ONE 6, e27496 (2011
175. Blivet-Van Eggelpoλl, M. J. et al.Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. J. Hepatol. 57, 108-115 (2012
176. Villanueva, A. & Llovet, J. M. Targeted therapies for hepatocellular carcinoma. Gastroenterology 140, 1410-1426 (2011
177. Grant, T. J. et al.Antiproliferative small-molecule inhibitors of transcription factor LSF reveal oncogene addiction to LSF in hepatocellular carcinoma. Proc. Natl Acad. Sci. USA 109, 4503-4508 (2012
178. Feitelson, M. A., Lian, Z., Liu, J., Tufan, N. L. & Pan, J. Parallel epigenetic and genetic changes in hepatitis B virus associated hepatocellular carcinoma. Cancer Lett. 239, 10-20 (2006
179. Baylin, S. B. & Ohm, J. E. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nature Rev. Cancer 6, 107-116 (2006
180. Popovic, R. & Licht, J. D. Emerging epigenetic targets and therapies in cancer medicine. Cancer Discov. 2, 405-413 (2012
181. Tiollais, P., Pourcel, C. & Dejean, A. The hepatitis B virus. Nature 317, 489-495 (1985
182. Rehermann, B. Hepatitis C virus versus innate and adaptive immune responses: A tale of coevolution and coexistence. J. Clin. Invest. 119, 1745-1754 (2009